TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03566810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test GXR
Description: Participants received a single oral dose of 500 mg of test GXR tablet (Merck Nantong/China) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test GXR
Description: Participants received a single oral dose of 500 mg of test GXR tablet (Merck Nantong/China) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test GXR
Description: Participants received a single oral dose of 500 mg of test GXR tablet (Merck Nantong/China) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test GXR
Description: Participants received a single oral dose of 500 mg of test GXR tablet (Merck Nantong/China) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference GXR
Description: Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/France) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference GXR
Description: Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/France) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference GXR
Description: Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/France) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference GXR
Description: Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/France) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
Study: NCT00171704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg tablets and supplied in bottles with 6-monthly supplies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg tablets and supplied in bottles with 6-monthly supplies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: 20 mg tablets in bottles as 6-monthly supplies (supplied to Novartis as Tamofen from Schering Oy, Subsidiary of Schering AG, Pansiontie 47, FIN-2010 Turku, Finland)
Study: NCT03763838

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupressure
Description: Six weeks of daily self-administered sham acupressure. Instructions will be provided for how to perform acupressure on self. A tool (AcuWand) will be provided to help participants apply the right amount of pressure; however, the points that participants are instructed to use are not known to have any effect on the body.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Fatigue management provided by participants' health care providers.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard of Care
Description: Fatigue management provided by participants' health care providers.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Fatigue management provided by participants' health care providers.
Study: NCT03006003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene
Description: Raloxifene tratment more than 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: Alendronic acid 70mg with Colecalciferol 70mcg
Study: NCT02586298

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous mitochondria with ICSI
Description: Autologous mitochondria during the intracytoplasmic sperm injection (ICSI) process will be added to this randomized group of oocytes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: STANDARD ICSI PROCEDURE
Description: STANDARD ICSI PROCEDURE
Study: NCT01658033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin + mFOLFOX6
Description: mFOLFOX6 regimen, repeated every 2 weeks: Oxaliplatin 85 mg/m2，ivgtt； Leucovorin 400 mg/m2,ivgtt； 5-FU 400 mg/m2，iv，and then 2400 mg/m2，civ46h；~Avastin: Avastin 5mg/kg q2w or 7.5mg/kg q3w
Study: NCT03367663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 20 Mg
Description: Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 40 Mg
Description: Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
Study: NCT02686749

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: During ablation, a doctor inserts a catheter through blood vessels into the heart. The doctor looks at the electrical activity of the heart. The catheter is used to determine which areas of the heart are causing AF. After the area is identified, the doctor uses a special machine delivers energy through the catheter to tiny areas of the heart muscle that is causing AF. This energy causes a scar in the tissue which disconnects the pathway of the AF.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FDA approved anti arrhythmic drug
Description: Anti arrhythmic drug medical treatment will be based on treating physicians discretion following standard clinical guidelines
Study: NCT04074889

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: (Microbial cell preparation) Probiotics
Description: Lactobacillus acidophilus (107mg), Lactobacillus casei subsp (107mg), Lactobacillus lactis (107mg), Bifidobacterium bifidum (107mg), Bifidobacterium infantis (107mg) and Bifidobacterium longum (107mg)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sachet with no microbial cell preparation
Study: NCT01652950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: The incentive arms comprised a Direct Payment Group, a Charity Incentive Group, a Lottery Pay-out Group, and a Choice Group. Members were offered the base program and supplementary communication described above. In addition, individuals were offered the equivalent of one of four possible incentive amounts depending on the level of participation in fitness-related activities. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.~Level 1: \<150 fitness points per month - equivalent to \< 1 gym visit per month - no reward, up to Level 5, which was \>3000 fitness points/month - equivalent to \>20 gym visits/month.
Study: NCT03142763

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eggs
Description: Consumption of 3 eggs per day for breakfast, 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Choline Supplement
Description: Consumption of choline supplement, 1 1/2 tablet (395mg choline), with breakfast for 4 weeks
Study: NCT00895674

Intervention type: DRUG
Intervention: Nexavar (Sorafenib, BAY43-9006)
Description: Patients with a diagnosis of advanced RCC
Study: NCT04112329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: will use the PlayPulse exergame for 45 minutes a minimum of two times per week for 8 weeks.
Study: NCT02591199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: URG101

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Study: NCT00265447

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: 3 months of strength training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic conditioning
Description: 3 months of aerobic conditioning

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Delayed exercise
Description: delayed exercise control group
Study: NCT02749630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to UTTR1147A administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to UTTR1147A administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to UTTR1147A administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTTR1147A
Description: Escalating doses of intravenously administered UTTR1147A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTTR1147A
Description: Escalating doses of intravenously administered UTTR1147A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTTR1147A
Description: Escalating doses of intravenously administered UTTR1147A
Study: NCT03296891

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PoCUS Guided Resuscitation of Shock
Description: Point-of-care ultrasound (PoCUS) will be used to guide resuscitation of the participant with shock. A PoCUS study will consist of limited echocardiography (LE) and thoracic ultrasound (TUS).
Study: NCT00215878

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: D-serine (~2g /day)
Description: Two 6 weeks treatment arms under a cross over design. In one arm adjuvant treatment with experimental medication (D-serine \~2g /day), in the second arm adjuvant treatment with placebo (\~2g /day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-serine (~2g /day)
Description: Two 6 weeks treatment arms under a cross over design. In one arm adjuvant treatment with experimental medication (D-serine \~2g /day), in the second arm adjuvant treatment with placebo (\~2g /day)
Study: NCT02315027

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Mesenchymal Stem Cells
Description: single dose of 1 × 10(7) cells intrathecally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Mesenchymal Stem Cells
Description: 2 doses of 5 × 10(7) cells intrathecally each 1 month (±4 days) apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Mesenchymal Stem Cells
Description: 2 doses of 1 × 10(8) cells intrathecally each 1 month apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Mesenchymal Stem Cells
Description: Ten doses of 5 x 10(7) (±20%) cells intrathecally six months (±1 month) apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Mesenchymal Stem Cells
Description: Ten doses of 2.5 x 10(7) (±20%) cells intrathecally six months (±1 month) apart
Study: NCT04768387

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Personalized microbiome diet
Description: The personalized nutrition model estimates the optimal micronutrient compositions for a required microbiome modulation. In this study, we computed the microbiome modulation needed for an IBS case, based on the IBS-indices generated by the machine learning models. According to that, the baseline microbiome compositions are perturbed randomly with a small probability p. Perturbed profiles are accepted with a probability proportional to the decrease in the IBS-index as suggested by Metropolis sampling. This Monte-Carlo random walk in the microbiome composition space is expected to meet a low IBS-index microbiome composition nearby the baseline microbiome composition of the patient with a minimal modulation. The personalized nutrition model, then, estimates the optimized nutritional composition needed for this individual, expecting to drive the IBS-index to lower values.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Personalized microbiome diet
Description: The personalized nutrition model estimates the optimal micronutrient compositions for a required microbiome modulation. In this study, we computed the microbiome modulation needed for an IBS case, based on the IBS-indices generated by the machine learning models. According to that, the baseline microbiome compositions are perturbed randomly with a small probability p. Perturbed profiles are accepted with a probability proportional to the decrease in the IBS-index as suggested by Metropolis sampling. This Monte-Carlo random walk in the microbiome composition space is expected to meet a low IBS-index microbiome composition nearby the baseline microbiome composition of the patient with a minimal modulation. The personalized nutrition model, then, estimates the optimized nutritional composition needed for this individual, expecting to drive the IBS-index to lower values.
Study: NCT00893282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BackStop
Description: BackStop in a gel plug that potentially prevents retropulsion during intracorporeal lithotripsy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intracorporeal lithotripsy without the use of an anti-retropulsion device
Study: NCT04124393

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colon Polypectomy
Description: Polyp search and resection will be performed entirely during the withdrawal phase in both WE and CO2 groups. Insertion inspection and polypectomy will not be performed. All polyps in the proximal colon, defined as cecum, ascending colon, hepatic flexure, and transverse colon, will be removed irrespective of their size and appearance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colon Polypectomy
Description: Polyp search and resection will be performed entirely during the withdrawal phase in both WE and CO2 groups. Insertion inspection and polypectomy will not be performed. All polyps in the proximal colon, defined as cecum, ascending colon, hepatic flexure, and transverse colon, will be removed irrespective of their size and appearance.
Study: NCT04099017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Joint mobilization
Description: This study ARM will received Mulligan joint mobilization and concomitant therapies in this group.~The following are the brief detail of therapy~1. Mulligan joint mobilization in Non-weight bearing (NWB) to weight-bearing (WB) 6 -10 Reps and 3 sets/ session.~   Procedural detail:~   Joint mobilization will be performed in sagittal, frontal and transverse direction, following glide will be preferred will depend on patient adherence to the joint mobilization. Mobilization will be progress from NWB to WB according to patient compliance 27~2. Knee strengthening Type of exercise: Knee Isometric Strengthening exercises. Intensity: 10 reps Frequency: At 1st week one set of all knee exercise will be performed then it will be progressed to 2 sets at 3 weeks, and these exercises will be progressed to three sets until the 6 weeks~3. Kinesiotaping:

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trunk stabilization group
Description: This study ARM will received Trunk stabilization exercises and concomitant therapies in this group.~The following are the brief detail of therapy:~1. Trunk stabilization Area: Trunk Type of exercise: Stabilization exercise Intensity: 6-8 reps Frequency: 3 sets per session and 30 second duration break between sets~   Procedural detail:~   i. modified supermen extension exercise ii. Back bridge: iii. Unilateral back bridge:~   Iv. lateral step up:~2. Knee strengthening Area: Knee Joint Type of exercise: Knee Isometric Strengthening exercises. Intensity: 10 reps Frequency: At 1st week one set of all knee exercise will be performed then it will be progressed to 2 sets at 3 weeks, and these exercises will be progressed to three sets until the 6 weeks~   Procedural detail:~   i. Isometric quadriceps exercise: ii. Straight leg raising (SLR) exercise:~3. Kinesiotaping:

Intervention type: OTHER
Group type: OTHER
Intervention: Knee strengthening group
Description: This study ARM will received Knee strengthening exercises and concomitant therapies in this group.~The following are the brief detail of therapy:~1. Knee strengthening Area: Knee Joint Type of exercise: Knee Isometric Strengthening exercises. Intensity: 10 reps Frequency: At 1st week one set of all knee exercise will be performed then it will be progressed to 2 sets at 3 weeks, and these exercises will be progressed to three sets until the 6 weeks~   Procedural detail:~   i. Isometric quadriceps exercise ii. Straight leg raising (SLR) exercise:~2. Kinesio-taping:~Muscle stretch method will be applied which involves one Y and two I straps: The Y-shaped tape base will be affixed over the top of patella then pulls up his/her knee to its maximum bending capacity then both end of Y strip is placed around the patella ending on the tibial tuberosity. Then reinforcing I-tape will be affixed at the origin and insertion of MCL and LCL. Tape will be change in every session.
Study: NCT03408054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin 10-5M solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin 10-5M solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: Nitroglycerin 25-1000mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: Nitroglycerin 25-1000mcg
Study: NCT02050230

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood transfusion
Description: One unit of red blood cells will be transfused over the course of 20 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood transfusion
Description: One unit of red blood cells will be transfused over the course of 20 minutes
Study: NCT03967639

Intervention type: PROCEDURE
Intervention: Elective cardiac surgery
Description: Elective cardiac surgery

Intervention type: PROCEDURE
Intervention: Elective cardiac surgery
Description: Elective cardiac surgery
Study: NCT00213291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa
Description: Darbepoetin alfa will be administered by SC/IV injection every 14-28 days. Patients starting on the 14 day dose regimen will receive two times their baseline weekly dose; patients on the 28 day schedule will receive four times their average weekly dose. The exception to a Q14 or Q28 dosing schedule will be for patients requiring 10 mcg every 10 days. These patients will go to 20 mcg Q21 days before extending to the Q28 day schedule. Naive patients will start on a dose of 0.9 mcg/kg every 14 days. Study subjects who are successfully treated for 12 weeks on the 14 day schedule may be enrolled in the 28 day schedule study.
Study: NCT01929980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study: NCT02895438

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: gluten

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: gluten
Study: NCT01778660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Type of Counselling (Mnemonic)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Study: NCT04131400

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Acuity Testing and Retinal Imaging
Description: All clinical and para- clinical tests including visual acuity assessment, perimetry, optical coherence tomography (OCT), enhanced depth- OCT, OCT angiography, color fundus, autofluorescence and infrared fundus photography will be performed